For the quarter ending 2026-03-31, INKT had -$3,834,664 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss on disposal of assets | - | - | -2,188 | -167,103 |
| Net loss | -2,742,368 | -2,602,103 | -2,887,709 | -7,004,448 |
| Depreciation | 36,066 | 38,563 | 43,654 | 99,528 |
| Share-based compensation | 630,386 | 565,771 | 620,585 | 1,487,641 |
| Loss on disposal of assets | - | -169,800 | - | - |
| Change in fair value of related party note | - | -571,100 | 193,920 | 532,012 |
| Interest accrued on related party note | - | 25,278 | 25,000 | 49,722 |
| Prepaid expenses | -11,910 | 23,352 | -21,016 | 27,452 |
| Accounts payable | -32,414 | -269,595 | 381,852 | 577,453 |
| Accrued liabilities and other current liabilities | 206,262 | 583,257 | 52,659 | 84,280 |
| Other operating assets and liabilities | -157,561 | -179,046 | -605,487 | -1,124,067 |
| Net cash used in operating activities | -1,732,597 | -2,073,726 | -941,348 | -2,910,094 |
| Net proceeds from sale of equity | 3,019,528 | 1,317,443 | 13,137,498 | - |
| Repayment of related party note | 5,000,000 | - | - | - |
| Payment for shares to satisfy tax withholdings | 251,768 | 173,353 | - | - |
| Proceeds from employee stock purchases and option exercises | 131,410 | 31,013 | 408,180 | 1,116 |
| Net cash provided by (used in) financing activities | -2,100,830 | 1,175,103 | 13,545,678 | 1,116 |
| Effect of exchange rate changes on cash | -1,237 | -22,249 | -5,033 | 13,853 |
| Net increase (decrease) in cash and cash equivalents | -3,834,664 | -920,872 | 12,599,297 | -2,895,125 |
| Cash and cash equivalents, beginning of period | 13,360,340 | 14,281,212 | 4,577,040 | - |
| Cash and cash equivalents, end of period | 9,525,676 | 13,360,340 | 14,281,212 | - |
MiNK Therapeutics, Inc. (INKT)
MiNK Therapeutics, Inc. (INKT)